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Abstract
Background: Limited data are available on the implementation of an area under the concentration-time curve (AUC)–based dosing protocol
with multidisciplinary team (MT) support to improve adherence with vancomycin dosing protocol.
Objective: To evaluate the effectiveness of an AUC-based dosing protocol with MT support intervention with adherence to a hospital-wide
vancomycin dosing protocol at Thammasat University Hospital.
Method: We conducted a quasi-experimental study in patients who were prescribed intravenous vancomycin. The study was divided into
2 periods; (1) the preintervention period when the vancomycin dosing protocol was already applied in routine practice and (2) the postintervention period when the implementation of an AUC-based dosing protocol with MT support was added to the existing vancomycin
dosing protocol. The primary outcome was the rate of adherence, and the secondary outcomes included acute kidney injury events,
vancomycin-related adverse events, and 30-day mortality rate.
Results: In total, 240 patients were enrolled. The most common infections were skin and soft-tissue infections (24.6%) and bacteremia (24.6%).
The most common pathogens were coagulase-negative staphylococci (19.6%) and Enterococcus spp (15.4%). Adherence with the vancomycin
dosing protocol was significantly higher in the postintervention period (90.8% vs 55%; P ≤ .001). By multivariate analysis, an AUC-based
dosing protocol with MT support was the sole predictor for adherence with the vancomycin dosing protocol (adjusted odds ratio, 10.31;
95% confidence interval, 4.54–23.45; P ≤ .001). The 30-day mortality rate was significantly lower during the postintervention period
(8.3% vs 20%; P = .015).
Conclusions: AUC-based dosing protocol with MT support significantly improved adherence with vancomycin dosing protocol and was
associated with a lower 30-day mortality rate.
(Received 15 April 2021; accepted 20 June 2021)

Existing guidelines suggest that using the ratio of area under the
concentration-time curve to minimal inhibitory concentration
(AUC/MIC) to guide dosing for vancomycin significantly
reduces vancomycin exposure and leads to improved treatment
effectiveness and lower nephrotoxicity.1 Such a strategy has been
adopted in developed countries and has led to improvements in
vancomycin therapeutic target attainment and to decreases in
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nephrotoxicity.2–4 AUC-guided dosing was recommended by a
revised consensus guideline from the American Society of HealthSystem Pharmacists (ASHP), the Infectious Diseases Society of
America (IDSA), the Pediatric Infectious Diseases Society (PIDS),
and the Society of Infectious Diseases Pharmacists (SIDP) for suspected or definitive serious methicillin-resistant Staphylococcus
aureus (MRSA) infections, patients at high risk for nephrotoxicity,
patients with unstable renal function, and those receiving prolonged
courses of therapy (ie, >3–5 days).1
In Asia, data regarding the use of AUC-guided vancomycin
dosing are limited to certain patent populations, including of pediatric, geriatric, and critically ill populations.5–8 The hospital-wide
use of AUC-guided vancomycin dosing has not been broadly
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implemented. Key barriers for routine implementation include
the prescribing culture, lack of time, lack of knowledge on vancomycin therapeutic dose monitoring, poor communication among
healthcare personnel, and poor coordination of the dose-monitoring
process.9,10
In Thailand, data on the routine use of hospital-wide AUC/MIC
guided vancomycin dosing strategies are limited.11,12 Furthermore,
the effectiveness of a multidisciplinary team (MT) with adherence
of a vancomycin dosing protocol has not been well studied.
To evaluate the feasibility of an AUC-based dosing protocol
with MT support to improve the hospital-wide adherence to AUCguided vancomycin dosing, we performed a quasi-experimental study
at a tertiary care center in Thailand.
Methods
We conducted a quasi-experimental study among hospitalized
patients who were admitted to Thammasat University Hospital,
a 600-bed tertiary-care medical center in central Thailand. In this
hospital, a standard antimicrobial stewardship program (ASP) was
established in 2004 and consisted of ID physicians, clinical microbiologists, general hospital pharmacists, a hospital epidemiologist,
an infection control specialist, and a computer system analyst.
A vancomycin dosing protocol has been available since 2011
and is based on 2009 guidelines from ASHP, IDSA, and SIDP.13
This protocol includes dose monitoring of vancomycin trough
concentration (eg, appropriate vancomycin dosing, appropriate
time to vancomycin concentration collections, adjusting vancomycin dosage base on optimal trough concentrations of 15–20 mg/L
for serious MRSA infections, and avoiding trough concentrations
of <10 mg/L or >20 mg/L). After physicians prescribed the first
dose of vancomycin, vancomycin trough concentration and dosage
adjustment were ordered based on physicians’ discretions. If an
ID consultation was requested, the ID consultant was the person
who ordered vancomycin. Although a hospital-wide vancomycin
dosing protocol was in place, there was no enforcement regarding
adherence to recommended vancomycin dosing, appropriate time
to vancomycin concentration collections, and adjustment of vancomycin dosages base on optimal trough concentrations. For this
reason, an MT was developed to monitor and reinforce adherence
to vancomycin dosing protocol.
The study was divided into 2 periods: (1) the preintervention
period (May–August 2020) when the vancomycin dosing protocol
was applied in routine practice and (2) the postintervention
period (October 2020–January 2021) when the implementation
of an AUC-based dosing protocol with MT support was added into
the existing hospital vancomycin dosing protocol. During the
postintervention period, we integrated new recommendations
on vancomycin dosing into a protocol featuring AUC-guided
vancomycin dosing.1 The MT consisted of infectious diseases
(ID) specialists, a clinical pharmacist, and laboratory technicians.
During the postintervention period, after physicians prescribe the
first dose of vancomycin, the clinical pharmacist reviewed vancomycin dosage and notified the ID specialist to monitor adherence
to the vancomycin dosing protocol for each prescription. This
process included monitoring weight-based dosing of vancomycin
and appropriate timing of vancomycin peak and trough concentrations collections within 72 hours after vancomycin initiation.
A clinical pharmacist then performed the AUC/MIC calculation
based on vancomycin concentrations and total vancomycin exposure per patient using online Bayesian software (Precise PK version
1.5.1.1.5.1, PrecisePK, San Diego, CA). After the AUC/MIC was
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calculated, the ID specialist contacted the treating physicians
regarding the need for appropriate adjustment or continuation
of current vancomycin dosage, as well as the need for the follow-up vancomycin concentrations via phone calls, chart notes,
messages, or direct contact. If the treating physicians did not comply with vancomycin dosing protocol, the ID specialist directly
communicated with treating physicians to explore the reasons
for noncompliance with the protocol as well as further suggestions
on appropriate vancomycin dosing based on specific situations.
Daily discussion on the quality improvement of AUC-guided
vancomycin dosing protocol was made by the team members
via social media (LINE application, LINE Corporation, Korea).
The protocol of vancomycin dosing during the postintervention
period is summarized in Supplementary Material 1 (online).
Eligible patients included adults (aged ≥18 years) who were
prescribed intravenous vancomycin therapy throughout the hospital for empirical therapy and targeted therapy for specific grampositive pathogens. The patients for whom vancomycin therapy
was stopped within 48 hours after initiation were excluded from
the study. We alsop excluded patients with pre-existing stage
4–5 chronic kidney disease,14 patients receiving renal replacement
therapy (RRT) prior to vancomycin initiation, and patients
currently on extracorporeal membrane oxygenation (ECMO).
We also collected data for patient characteristics their underlying
diseases, Charlson comorbidity index, baseline serum creatinine,
follow-up serum creatinine on days 2–7 after vancomycin dose,
hospital units, site of infection, and causative pathogens, concurrent nephrotoxicity agents as well as barriers to adherence to
vancomycin dosing protocol. Acute kidney injury was defined,
according to the Kidney Disease: Improving Global Outcomes
(KDIGO) clinical practice guidelines,15 as any of the following:
(1) increase in serum creatinine by ≥0.3 mg/dL within 48 hours,
or (2) increase in serum creatinine to ≥1.5 times baseline within
the prior 7 days, or (3) urine output volume <0.5 mL/kg/h for
6 hours. The MIC value was determined using the E-test
method (MICEtest) (M.I.C.Evaluator Strip; Thermo Fisher Scientific,
Basingstoke, UK).
The primary outcome included adherence of treating
physicians to the vancomycin dosing protocol or the recommendation of the MT, which was classified as appropriate if vancomycin prescriptions met all of the following adherence criteria:
(1) appropriate weight-based vancomycin dosing, (2) appropriate
time of vancomycin concentration collections (peak and trough
concentrations), and (3) appropriate adjustment or continuation
of vancomycin dosage as recommended by the hospital vancomycin dosing protocol or by the MT. The vancomycin trough
concentration (Ctrough) was defined as the serum vancomycin concentration obtained within 30 minutes prior to vancomycin next
dose. The vancomycin peak concentration (Cpeak) was the serum
vancomycin concentration obtained 1–2 hours after the completion of intravenous vancomycin dosage. The secondary outcomes
included acute kidney injury events, vancomycin-related adverse
events, length of hospital stay, and 30-day mortality rate. Based
on a prior survey of the adherence rate to vancomycin dosing protocol in our hospital, the sample size needed to achieve statistical
power of 80% to detect 25% improvement in adherence of treating
physicians to the vancomycin dosing protocol was 240 total
patients (120 patients per period).
The descriptive data are presented in number (percentage) and
mean with standard deviation (SD) or median with interquartile
range (IQR) depended on data distribution. Percentages were compared using χ2 tests or the Fisher exact test as appropriate, while the
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continuous data using the Mann-Whitney U test or the Student
t test. Multivariable logistic regression analysis was performed to
determine factors associated with adherence and 30-day mortality.
The P value of <.05 was considered statistically significant.
Statistical analyses were performed using SPSS Statistics software,
version 26 (IBM, Armonk, NY). This study was approved by the
institutional review board.
Results
In total, 240 patients were included in the study: 120 in the
preintervention period and 120 in the postintervention period.
The mean age for the study population was 59±19 years;
119 participants were male (49.6%); and the mean body weight
was 59.7±13.5 kg. Intravenous vancomycin was initiated in the
critical care setting in 24 patients (10%), and 216 patients (90%)
received vancomycin in a non–critical-care setting, including
a medical unit (n = 88, 36.7%) and a general surgical unit (n = 40,
18.3%) (Table 1). The most common comorbidities were hypertension (n = 108, 45%) and diabetes mellitus (n = 63, 26.3%)
(Table 1). The mean Charlson comorbidity index was 3.9±2.6.
Vancomycin was used for empirical therapy in 106 patients
(44.2%) and targeted therapy for specific gram-positive pathogens
in 134 patients (55.8%). The most common infections leading to
initiation of intravenous vancomycin therapy were bacteremia
(n = 59, 24.6%) and skin and soft-tissue infections (n = 59,
24.6%), followed by infections of central nervous system (n = 34,
14.2%). The most common pathogens isolated were coagulasenegative staphylococci (n = 47, 19.6%), Enterococcus spp (n = 37,
15.4%), and Corynebacterium spp (n = 26, 10.8%). MRSA infections occurred in only 9 patients (3.8%). The median MICEtest
for MRSA was 1 mg/L (interquartile range [IQR], 0.5–1 mg/L).
Only 1 MRSA isolate had an MICEtest value of 2 mg/L. Also,
17 patients (7.1%) received concurrent nephrotoxicity agents
for >2 days. Such agents included deoxycholate amphotericin B
(n = 7, 2.9%), colistin (n = 6, 2.5%), aminoglycoside (n = 3,
1.3%), and trimethoprim-sulfamethoxazole (n = 3, 1.3%).
Furthermore, 41 patients (17.1%) received concurrent piperacillin-tazobactam for >48 hours. Also, 21 patients (8.8%) had preexisting stage 3 chronic kidney disease. Furthermore, 5 patients
(2.1%) received a greater-than-maximum vancomycin dose of
>4 g/day; all of these were in the preintervention group. The baseline characteristics of the study population in the pre- and postintervention periods are compared in Table 1.
In the postintervention period, the adherence rate of vancomycin dosing protocol was significantly higher compared to the
preintervention period (90.8% vs 55%; P ≤ .001). Overall, we
detected no difference in adherence outcomes between patients
in the intensive care unit (ICU) and non-ICU settings (70.8 vs
73.6%; P = .77). Barriers of adherence to the vancomycin dosing
protocol in the postintervention period included a lack of knowledge about vancomycin therapeutic dose monitoring (7 of 11,
63.6%) and poor communication among healthcare personnel
(4 of 11, 36.4%). Patients who received weight-based loading dose,
met appropriate time to vancomycin concentration collections,
and had appropriate dosage adjustment and monitoring were
significantly higher in postintervention period: 71.7% vs 41.7%
(P ≤ .001), 96.7% vs 81.7% (P ≤ .001), and 90.8% vs 55.8%
(P ≤ .001), respectively (Table 2). Among the 240 patients include
in this study, 19 patients (7.9%) developed acute kidney injury during vancomycin therapy. We detected a trend toward lower rate of
acute kidney injury in the postintervention period compared to the

3

preintervention period (5.0% vs 10.8%; P = .15). Overall, the
30-day mortality rate among the whole study cohort was 7.9%
(34 of 240). We detected a statistically significant lower in the
30-day mortality rate during the postintervention period (8.3%
vs 20%; P = .015). Vancomycin-related adverse events were found
in 9 patients (9 of 240, 3.8%). Most were minor drug eruptions
(7 of 240, 2.9%); 1 patient had red-man syndrome and 1 patient
developed a drug reaction with eosinophilia and systemic
symptoms (both patients were in the preintervention group). No
instance of ototoxicity was reported in patients during the entire
study period.
By multivariate logistic regression analysis of the adherence to
the vancomycin dosing protocol, the factor predicting adherence to
vancomycin dosing protocol included the AUC-based dosing protocol with MT support (adjusted odd ratio [aOR], 10.31; 95% CI,
4.54–23.45; P ≤ .001). In contrast, CNS infections (aOR, 0.18; 95%
CI, 0.07–0.43; P ≤ .001) and eye infections (aOR, 0.09; 95% CI,
0.02–0.42; P = .002) were associated with lower adherence to
the vancomycin dosing protocol. The factor associated with a lower
rate of 30-day mortality was the AUC-based dosing protocol with
MT support (aOR, 0.23; 95% CI, 0.08–0.64; P = .005), whereas
admission to ICU (aOR, 3.57; 95% CI, 1.03–12.42; P = .046), solid
malignancy (aOR, 9.50; 95% CI, 2.86–31.50; P ≤ .001), and diagnosis of bacteremia (aOR, 3.86; 95% CI, 1.48–10.04; P = .006) were
associated with higher mortality (Table 3). We detected no
statistically differences in other secondary outcomes including
acute kidney injury, vancomycin-related adverse events and length
of hospitalization (Table 2).
Discussion
This study contributes 4 notable findings. First, an AUC-based
dosing protocol with MT support was feasible and highly effective
to improve adherence to a vancomycin dosing protocol among
ICU and non-ICU settings in an Asian hospital. Second, compliance with vancomycin dosing protocol featuring AUC-guided dose
monitoring can lead to a reduction in overall mortality and a trend
toward reduction in nephrotoxicity. Third, the AUC-based dosing
protocol with MT support was effective in improving adherence on
vancomycin dosing protocol among patients who receive vancomycin as empirical therapy or as targeted therapy for specific grampositive pathogens. Lastly, this AUC-based dosing protocol with
MT support was well accepted by treating physicians, as demonstrated by the high adherence rate to the vancomycin dosing protocol.
Strategies to improve vancomycin dosing protocol adherence
have included education interventions, computer-assisted decision
making in vancomycin prescriptions, pharmacist-driven vancomycin therapeutic dose monitoring program, and prospective
review and feedback of vancomycin use.16–22 However, these interventions were performed to improve vancomycin prescriptions in
the era of using trough-guided vancomycin dosing. Limited data
are available on effectiveness of AUC-based dosing protocol
with MT support to improve AUC-guided vancomycin dosing
protocols. To our knowledge, our study is the first to report the
effectiveness of hospital-wide AUC-based dosing protocol with
MT support to improve adherence to AUC-guided vancomycin
dosing protocol in Asia. Notably, several factors, including CNS
infections and eye infections, were associated with lower adherence
to the vancomycin dosing protocol. Most noncompliance events
occurred during the preintervention period and were associated
with the combination of the lack of knowledge on vancomycin
therapeutic dose monitoring and prescribing behaviors.
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Table 1. Baseline Characteristics
Total (N = 240)

Characteristics
Age mean y ± SD

Preintervention Period (n = 120)

Postintervention Period (n = 120)

P Value

59 ± 19

57 ± 20

60 ± 19

.208

Sex, male

119 (49.6)

60 (50)

59 (49.2)

1.000

Body weight (kg), mean ± SD

59.7 ± 13.6

59 ± 14

60.2 ± 13.2

.396

Units
ICU
Non-ICU

24 (10)

11 (9.2)

13 (10.8)

.830

216 (90)

109 (90.8)

107 (89.2)

.830

Medical unit

88 (36.7)

44 (36.7)

44 (36.7)

1.000

Surgical unit

40 (18.3)

24 (20)

16 (13.3)

.225

Neurosurgical unit

34 (14.2)

16 (13.3)

18 (15)

.853

Orthopedic unit

26 (10.8)

14 (11.7)

12 (10)

.835

Other unitsa

28 (11.7)

11 (9.2)

17 (14.2)

.315

Underlying disease
HTN

108 (45)

DM
Solid malignancy
Other underlying diseasesb
Charlson comorbidity index, mean ± SD

50 (41.7)

58 (48.3)

.364

63 (26.3)

33 (27.5)

30 (25)

.769

61 (25.4)

27 (22.5)

34 (28.3)

.374

138 (57.5)

74 (61.7)

64 (53.3)

.192

3.9 ± 2.6

3.8 ± 2.7

3.9 ± 2.4

.553

199 (82.9)

100 (83.2)

99 (82.5)

1.000

SSTI

59 (24.6)

27 (22.5)

32 (26.7)

.549

Bacteremia

59 (24.6)

29 (24.2)

30 (25)

1.000

CNS infection

34 (14.2)

17 (14.2)

17 (14.2)

1.000

Eye infection

12 (5)

9 (7.5)

3 (2.5)

.136

Otherc

76 (31.7)

38 (31.7)

38 (31.7)

1.000

Targeted therapy for specific gram-positive pathogens

134 (55.8)

61 (50.8)

73 (60.8)

.153

Empirical therapy

106 (44.2)

59 (49.2)

47 (39.2)

.153

20 (8.3)

9 (7.5)

11 (9.2)

.816

11 (4.6)

4 (3.3)

7 (5.8)

.539

ID consultation
Site of infection

Indications

Isolated pathogens
Staphylococcus aureus
MSSA
MRSA

9 (3.8)

5 (4.2)

4 (3.3)

1.000

CONS

47 (19.6)

22 (18.3)

25 (20.8)

.745

Enterococcus spp

37 (15.4)

21 (17.5)

16 (13.3)

.475

Corynebacterium spp

26 (10.8)

9 (7.5)

17 (14.2)

.145

4 (3.33)

4 (3.33)

1.000

7 (5.8)

.616

0 (0)

.060

Other pathogens

d

Concurrent nephrotoxic agent > 2 dayse
Supratherapeutic doses of vancomycin (> 4 g/day)

8 (3.33)
17 (7.1)

10 (8.3)

5 (2.1)

5 (4.2)

Note. ICU, intensive care unit; HTN, hypertension; DM, diabetes mellitus; ID, infectious diseases; SSTI, skin and soft-tissue infection; CNS, central nervous system; S. aureus, S. aureus; MSSA,
methicillin-susceptible S. aureus; MRSA, methicillin-resistant S. aureus; CONS, coagulase-negative staphylococci; N/A, not applicable.
a
Other units included ophthalmic unit; ear, nose, and throat unit; and obstetrics and gynecology unit.
b
Other underlying diseases included coronary artery disease, stage 3 chronic kidney disease, chronic liver disease, chronic lung disease, hematologic malignancy, history of cerebrovascular
accident, autoimmune disease, and human immunodeficiency virus infection.
c
Other site of infections included respiratory tract infection, bone and joint infection, intraabdominal infection, urinary tract infection, endovascular infection, and unknown site of infection.
d
Other pathogens included Streptococci spp, Bacillus spp, and Rhodococcus kroppenstedtii.
e
Concurrent nephrotoxic agents included deoxycholate amphotericin B, colistin, aminoglycoside, trimethoprim-sulfamethoxazole, angiotensin-converting enzyme inhibitors, nonsteroidal
anti-inflammatory drugs, and diuretics.

Barriers for nonadherence to vancomycin dosing protocols
have included a lack of knowledge and clear communication on
vancomycin dose-monitoring processes, a lack of a committed

antimicrobial stewardship (ASP) team, physician prescribing
behavior, and a lack of resources for dose calculation.9,23 In our
study, the AUC-based dosing protocol with MT support improved
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Table 2. Primary and Secondary Outcomes
Total (N = 240)

Preintervention Period (n = 120)

Postintervention Period (n = 120)

P Value

Appropriate loading dose

136 (56.7)

50 (41.7)

86 (71.7)

≤.001

Appropriate weight-based dosing

234 (97.5)

115 (95.8)

119 (99.7)

.231

Appropriate time to concentration collections

214 (89.2)

98 (81.7)

116 (96.7)

≤.001

Outcome
Primary outcomes

Appropriate adjustment and monitoring

176 (73.3)

67 (55.8)

109 (90.8)

≤.001

Met all adherence criteria

175 (72.9)

66 (55)

109 (90.8)

≤.001

Secondary outcomes
Acute kidney injury

19 (7.9)

13 (10.8)

30-day mortality

34 (14.2)

Vancomycin-related adverse events
Length of hospitalization, mean d ± SD

6 (5)

.150

24 (20)

10 (8.3)

.015

9 (3.8)

7 (5.8)

2 (1.7)

.171

38 ± 27.5

34.6 ± 25.2

41.5 ± 29.3

.061

Note. SD, standard deviation.

Table 3. Multivariate Analysis of Factors Associated With Adherence to
Vancomycin Dosing Protocol and 30-Day Mortality
Variable

aOR

95% CI

P Value

Adherence to vancomycin dosing protocol
10.31 4.54–23.45

≤.001

CNS infection

0.18 0.07–0.43

≤.001

Eye infection

0.09 0.02–0.42

.002

AUC-based dosing protocol with MT
support

0.23 0.08–0.64

.005

ICU admission

3.57 1.03–12.42

.046

Solid malignancy

9.50 2.86–31.50

≤.001

Bacteremia

3.86 1.48–10.04

.006

AUC-based dosing protocol with MT
support

30-day mortality

Note. MT, multidisciplinary team; CNS, central nervous system; ICU, intensive care unit.

adherence to the vancomycin dosing protocol was well accepted
by physicians with only 9.17% nonadherence to the vancomycin
dosing protocol. Significant barriers for adherence to vancomycin
dosing protocol in our study included a lack of knowledge
about vancomycin therapeutic dose monitoring and poor communication among healthcare personnel (eg, physicians, nurses,
pharmacists, ID physicians) who are involved in vancomycin
administration.
Previous data suggested that AUC-guided vancomycin dosing
can lead to lower vancomycin exposure, leading to reductions in
nephrotoxicity and other vancomycin-related adverse events
(eg, drug eruptions, red man syndrome), improved resolution of
signs and symptoms of infection, reduction in time to bacterial
eradication, and decreased treatment failure and mortality.4,24–30
The treatment outcome measures of AUC-guided vancomycin
dosing in previous studies included resolution of signs and symptoms, bacterial eradication, treatment failure, mortality, nephrotoxicity, and other vancomycin-related adverse events.25–30
Our study confirmed that hospital-wide use of an AUC-based
dosing protocol with MT support may lead to reduction in
30-day mortality and a trend toward reduction in nephrotoxicity
and vancomycin-related adverse events. Notably, severity of illness,

immunocompromised status, diagnosis of bacteremia and receive of
concomitant nephrotoxicity agents remained important predictors
for higher mortality.
Our study has several limitations. First, we used a quasiexperimental study design which may be subject to temporal
changes in the patient population over time. However, the baseline
characteristics of patients in the pre- and postintervention periods
were comparable. Second, this was a single-center study, which
may limit the generalizability of our findings. Third, we did not
collect the impact of AUC-guided vancomycin dosing protocol
on treatment outcomes specific for each gram-positive pathogen.
Fourth, we used the E-test method for measuring MRSA MICs, which
may have overestimated the true MIC. However, the number of
MRSA infections in our study was small. Lastly, the small sample size
in this study limited our power to detect changes in outcome results.
In conclusion, an AUC-based dosing protocol with MT strategy
was effective to improve adherence to vancomycin dosing protocol
in this middle-income country. This strategy can be readily applied
without substantial barriers. Reduction in vancomycin exposure
facilitated by this strategy may lead to reduction in nephrotoxicity
and 30-day mortality. Additional studies to evaluate this strategy
on various indications (eg, empirical versus targeted therapy for
specific gram-positive pathogens), various outcomes including
treatment outcomes on specific gram-positive pathogens, as well
as cost-effectiveness of such strategy in Asia are needed.
Supplementary material. To view supplementary material for this article,
please visit https://doi.org/10.1017/ice.2021.296
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